© 2007 Cardinal Health. All rights reserved. Marketing PET in Radiation Treatment Planning PET Marketing Forum – Accelerating Practice Growth May 23, 2007.
Overview of Current and future Contrast Agent and Statistical and design issues in clinical development of contrast agents Kohkan Shamsi, MD, PhD President,
Standard and Advanced Tumor Response Analysis using 3D Slicer Title change? Images & Acknowledgements…
International Atomic Energy Agency L 2 PET/CT TECHNOLOGY.
Herceptin as a Phase 0 Imaging Example. Phase 0 Trials in Oncology Drug Development Steven M. Larson, M.D. Nuclear Medicine Svc, Department of Radiology.
Radiological Category: Case Report Submitted by:Matthew Bean MSIV Faculty reviewer:Sandra Oldham M.D Date accepted: August 28, 2014 Principal Modality.
“International Conference on Clinical PET and Molecular Nuclear Medicine” IAEA - IPET 2007 Bangkok, Thailand 10 to 14 November 2007 C. Suarez, R. Pruzzo,
BSUGIS Spring Meeting March 18, 2014 Lieven Depypere, Willy Coosemans, Georges Decker, Hans Van Veer, Philippe Nafteux Department of thoracic surgery,
Imaging of Lymphoma Dr.: Adel El-Badrawy Assistant Professor of Radiology Mansoura Faculty of Medicine.
Total Lesion Glycolysis by 18 F-FDG PET/CT a Reliable Predictor of Prognosis in Soft Tissue Sarcoma Ilkyu Han Musculoskeletal Tumor Center, Seoul National.
PET/CT & PET/MRI Radiopharmacy 10. Positron emission tomography (PET) and computerized tomography (CT) are both state-of-the-art imaging tools that allow.
